HUTCHMED (China) Limited American Depositary Shares (HCM)

HUTCHMED introduced its Antibody-Targeted Therapy Conjugate (ATTC) platform, focusing on a novel approach to cancer treatment using targeted therapies with dual mechanisms of action. The lead candidate HMPL-A251 demonstrates promising preclinical efficacy in targeting HER2-positive tumors with improved safety profiles.

Hutchmed divests 45% equity in SHPL for $608 million, allowing it to focus on its core cancer drug development business. The company also received priority review for a lung cancer drug combination from China's NMPA.

HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

After years of ‘lackluster’ efforts, regulators and companies are finally aligned in their goal to make clinical trials more representative of U.S. population.

The risks of investing in Chinese stocks are growing.